Journal
ONCOIMMUNOLOGY
Volume 2, Issue 12, Pages -Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/onci.26617
Keywords
anti-cytokine therapy; colitis-associated colon cancer; IL-17A; IL-17F; IL-21; IL-22; inflammation; NF kappa B; STAT3; T(H)17 cells
Categories
Funding
- Fondazione Umberto di Mario ONLUS, Rome
- AIRC [MFAG-12108, IG-13049]
- Giuliani SpA, Milan, Italy
Ask authors/readers for more resources
Immune/inflammatory cells infiltrate almost all human solid tumors and affect all stages of carcinogenesis as they produce different cytokine subsets. The overproduction of T(H)17 cytokines marks the early stages of colorectal carcinoma (CRC) and negatively influences the prognosis of CRC patients. Studies with murine models of CRC have delineated the mechanisms by which T(H)17 cytokines, notably, interleukin (IL)-17A, IL-17F, IL-21, and IL-22, regulate oncogenesis and tumor progression, paving the way to the development of novel anticancer drugs. In this review article, we discuss experimental data supporting the role of T(H)17 cytokines in the modulation of colorectal tumorigenesis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
